comparemela.com
Home
Live Updates
FDA Approves Companion Diagnostic for Mobocertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations : comparemela.com
FDA Approves Companion Diagnostic for Mobocertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations
The FDA has approved FoundationOne® Liquid CDx as a companion diagnostic for mobocertinib in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations.
Related Keywords
Stefanie Granado ,
Takeda Exkivity ,
Takeda Pharmaceutical Company ,
Foundation Medicine ,
Business Unit ,
Torsades De Pointes ,
Mobocertinib ,
Egfr Exon 20 Insertion ,
Egfr ,
Nsclc ,
Non Small Cell Lung Cancer ,
Lung Cancer ,
Companion Diagnostic ,
Foundationone ,
Foundationone Liquid Cdx ,
Exkivity ,
Fda ,
Fda Approval ,
comparemela.com © 2020. All Rights Reserved.